European Medicines Agency

Don’t put the kibosh on innovation

The European Medicines Agency’s thumbs-down for rare disease treatment Glybera flies in the face of Commission policy. It’s also against the wishes of the European Parliament, and the impetus DG Sanco is putting into Orphan Drugs. Worse still, it’s bad for patients and kills innovation. By Nuala Moran.
25 Apr 2012

Patients take control of innovation

Despite industry’s endless lip service to driving innovation for the benefit of patients, many diseases go untreated. Now, sick of being passive recipients, patients are taking control and shaping innovation to their real needs
22 Jul 2011